A recent trial has suggested that it may be safely used in the management of patients with thrombotic APS and might offer a convenient alternative to warfarin in this subgroup of patients with APS52.Therefore, our findings of the effect of FXa inhibitors upon in-vitro cellular effects of FXa-reactive APS IgG may provide additional evidence to support the use of FXa inhibitors in patients with APS. The gene discussed is F10; the disease is autoimmune polyendocrinopathy.